The Federal Circuit, over Celltrion’s opposition, has granted Janssen’s motion for a 30-day extension of time to file its opening appeal brief. Janssen’s opening brief is now due on January…
The Federal Circuit, over Celltrion’s opposition, has granted Janssen’s motion for a 30-day extension of time to file its opening appeal brief. Janssen’s opening brief is now due on January…
The European Crohn’s and Colitis Organisation (“ECCO”) released a statement last week supporting the switch from the reference infliximab to biosimilar infliximab in patients…
This past April, the FDA approved Inflectra® (infliximab-dyyb), Celltrion and Hospira’s biosimilar of Janssen’s Remicade®. According to papers filed in the Federal Circuit this week,…
The past few days have seen a lot of activity on the rituximab biosimilar front. According to a joint press release, Sanofi and JHL Biotech, a biopharmaceutical company based in…
On November 15, 2016, the U.S. District Court for the District of Utah entered a stipulated order to stay Janssen’s pending lawsuit against HyClone Laboratories, which supplies cell culture media…
Below is our Fall 2016 update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or…
On this blog, we have been following two Celltrion biosimilars: CT-P10 (rituximab) and CT-P13 (infliximab, the subject of the Janssen v. Celltrion litigation). According to a Celltrion press…
The appeal from Janssen Biotech, Inc. v. Celltrion Healthcare Co. (D. Mass. No. 15-10698) has been docketed at the Federal Circuit with the number 17-1120. Janssen’s opening brief is due…
According to The Korea Herald, the South Korean biopharma company Celltrion submitted their Herceptin biosimilar, Herzuma, to the European Medicine Agency for approval. Herzuma, a biosimilar to…
As we previously reported, on September 26, 2016, the district court in Janssen v. Celltrion entered partial final judgment that the ’471 patent, asserted by Janssen, was invalid. Today,…